PARP1 and ovarian carcinoma: The latest PARP inhibitor to be approved by the FDA is niraparib, based on the phase III NOVA study that investigated the role of this PARP 1/2 inhibitor as maintenance therapy for patients with platinum-sensitive, recurrent ovarian cancer.